Stock Details
ALPMF is Astellas Pharma Inc.'s stock. Stock exchange Other OTC (Currency USD). Average price in 50 days is 14.48$. Average daily volumn in 3 months 1.98k. Market cap 26.03B



Stock symbol : ALPMF. Exchange : Other OTC. Currency : USD
Lastest price : 13.71$. Total volume : 500.00. Market state POST
Click reload if you want to check the lastest price on market!!!

Astellas Pharma Inc. (ALPMF)
Last Price
13.71$
Change
0.75
Volume
500.00

Previous Close12.96
Open13.71
Day Range13.71-13.71
Bid0.00 x N/A
Ask0.00 x N/A
Volume500
Average Volume1.98k
Market Cap26.03B
Beta0.56
52 Week Range12.77-17.95
Trailing P/E29.80
Foward P/EN/A
Dividend (Yield %)3.69%
Ex-Dividend Date2023-03-30



Financial Details


According to Astellas Pharma Inc.'s financial reports the company's revenue in 2022 were 1.3T an increase(0%) over the years 2021 revenue that were of 1.25T. In 2022 the company's total earnings were 124.09B while total earnings in 2021 were 120.59B( +3.33%).


Loading ...



Organization

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatme... nt of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Market Cap:
26.03B
Revenue:
1.3T
Total Assets:
2.33T
Total Cash:
315.99B


News about "Astellas Pharma Inc."

astellas-pharma-and-pantherna-therapeutics-enter-new-technology-evaluation-agreement-image

Astellas Pharma and Pantherna Therapeutics Enter New Technology Evaluation Agreement

Source from : Contract Pharma - 14 hours ago

Pantherna's mRNA platform & Astellas' drug discovery capabilities will be combined to generate mRNA-based regenerative medicine programs.See details»


Astellas Pharma Inc. ADR

Source from : Wall Street Journal - 21 days ago

1 Day ALPMY -1.91% DJIA -3.54% S&P 500 -3.90% Health Care/Life Sciences -0.27% Kenji Yasukawa President, CEO & Representative Director Astellas Pharma SpA, Astellas Pharma, Inc. Naoki Okamura ...See details»


treatment-for-hot-flushes-and-night-sweats-accepted-for-regulatory-review-by-ema-image

Treatment for hot flushes and night sweats accepted for regulatory review by EMA

Source from : labiotech - 1 days ago

Astellas' fezolinetant treatment for moderate to severe vasomotor symptoms has been accepted by the EMA for regulatory review.See details»


Astellas Pharma Inc. (4503)

Source from : Investing - 5 days ago

Investing.com โ€“ Japan stocks were lower after the close on Thursday, as losses in the Mining, Power and Precision Instruments sectors led shares lower. At the close in Tokyo, the ...See details»


Astellas : EMA Accepts Marketing Authorization Application For Fezolinetant

Source from : Nasdaq - 4 days ago

(RTTNews) - Astellas Pharma Inc. said that the European Medicines Agency or EMA has accepted for regulatory review the company's marketing authorization application or MAA for fezolinetant ...See details»


Astellas confirms US District Court decision for an interim injunction against Hospira for Lexiscan

Source from : Pharmabiz - 7 days ago

Astellas Pharma Inc. confirms the US District Court for the District of Delawareโ€™s order granting an interim injunction enjoining Hospira from launching its generic version of Lexiscan until October 5 ...See details»


European Medicines Agency Accepts Astellas' Marketing Authorization Application for Fezolinetant

Source from : Yahoo Finance - 5 days ago

29, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the European Medicines Agency (EMA) has accepted for regulatory ...See details»


Mixed news for Astellas regarding Lexiscan patent dispute

Source from : The Pharma Letter - 8 days ago

Astellas Pharma (TYO: 4503) saw its share gain 1.6% in early trading, though they drifted back, as it revealed it has won a reprieve in its patent dispute with generics and biosimilar injectables ...See details»


Astellas facing generics to big-selling Lexiscan product in US

Source from : pharmaphorum - 8 days ago

Lexiscan was originally developed by CV Therapeutics, which licensed rights to the drug to Astellas shortly before the Japanese pharma launched a hostile bid for the company โ€“ thwarted when it ...See details»


EMA accepts Astellasโ€™ filing for fezolinetant

Source from : The Pharma Letter - 4 days ago

Supporting the filing are results fromโ€ฆ โ€ข All the news that moves the needle in pharma and biotech. โ€ข Exclusive features, podcasts, interviews, data analyses and commentary from our global network of ...See details»


European Medicines Agency Accepts Astellas'...

Source from : Benzinga.com - 5 days ago

"More than half of women 40 to 64 years of age experience hot flashes during menopause, with limited nonhormonal treatment options," said Ahsan Arozullah, M.D., M.P.H., Senior Vice President and ...See details»


usfda-approves-lupins-extended-release-tablets-for-overactive-bladder-image

USFDA approves Lupinโ€™s extended release tablets for overactive bladder

Source from : The Financial Express on MSN - 5 days ago

Mirabegron is indicated to treat overactive bladder or neurogenic detrusor overactivity but does not cure these conditions.See details»


Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts

Source from : Yahoo Finance - 15 days ago

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators TOKYO and SAN FRANCISCO, Sept. 19, 2022 /PRNewswire ...See details»


lupin-bags-usfda-approval-for-mirabegron-er-tablets-to-treat-overactive-bladder-image

Lupin bags USFDA approval for Mirabegron ER tablets to treat overactive bladder

Source from : Daily - 4 days ago

Mirabegron is indicated for treating the overactive bladder or neurogenic detrusor overactivity but does not cure these conditions. Read also: Lupin unveils Sodium Sulfate, Potassium Sulfate and ...See details»